Abstract:Cytochrome P450 enzymes (P450s) are important in drug metabolism and have been linked to adverse drug reactions. P450s display broad substrate reactivity, and prediction of metabolites is complex. QM/MM studies of P450 reactivity have provided insight into important details of the reaction mechanisms and have the potential to make predictions of metabolite formation. Here we present a comprehensive study of the oxidation of three widely used pharmaceutical compounds (S-ibuprofen, diclofenac, and S-warfarin) by one of the major drug-metabolizing P450 isoforms, CYP2C9. The reaction barriers to substrate oxidation by the iron-oxo species (Compound I) have been calculated at the B3LYP-D/CHARMM27 level for different possible metabolism sites for each drug, on multiple pathways. In the cases of ibuprofen and warfarin, the process with the lowest activation energy is consistent with the experimentally preferred metabolite. For diclofenac, the pathway leading to the experimentally observed metabolite is not the one with the lowest activation energy. This apparent inconsistency with experiment might be explained by the two very different binding modes involved in oxidation at the two competing positions. The carboxylate of diclofenac interacts strongly with the CYP2C9 Arg108 side chain in the transition state for formation of the observed metabolite-but not in that for the competing pathway. We compare reaction barriers calculated both in the presence and in the absence of the protein and observe a marked improvement in selectivity prediction ability upon inclusion of the protein for all of the substrates studied. The barriers calculated with the protein are generally higher than those calculated in the gas phase. This suggests that active-site residues surrounding the substrate play an important role in controlling selectivity in CYP2C9. The results show that inclusion of sampling (particularly) and dispersion effects is important in making accurate predictions of drug metabolism selectivity of P450s using QM/MM methods.

Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains

The use of isomeric testosterone dimers to explore allosteric effects in substrate binding to cytochrome P450 CYP3A4

Induction of Diphenytriazol on Cytochrome CYP1A.

[Metabolism-Based Interaction of Diphenytriazol and Flavone Compounds].

Unraveling the Structural Basis of Selective Inhibition of Human Cytochrome P450 3A5

Structural dynamics of cytochrome P450 3A4 in the presence of substrates and cytochrome P450 reductase

Comparison of catalytic properties of cytochromes P450 3A4 and 3A5 by molecular docking simulation

Defining CYP3A4 structural responses to substrate binding. Raman spectroscopic studies of a nanodisc-incorporated mammalian cytochrome P450.

The Crystal Structures Of 4-Methoxybenzoate Bound Cyp199a2 And Cyp199a4: Structural Changes On Substrate Binding And The Identification Of An Anion Binding Site

Identification of New Substrates and Inhibitors of Human CYP2A7

Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes

Molecular docking and oxidation kinetics of 3-phenyl coumarin derivatives by human CYP2A13

Differences of Atomic-Level Interactions between Midazolam and Two CYP Isoforms 3A4 and 3A5

Influence Of Various Polymorphic Variants Of Cytochrome P450 Oxidoreductase (Por) On Drug Metabolic Activity Of Cyp3a4 And Cyp2b6

Quantum Mechanics/Molecular Mechanics Modeling of Regioselectivity of Drug Metabolism in Cytochrome P450 2C9

Molecular determinant of substrate binding and specificity of cytochrome P450 2J2

Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.

Substrate Selectivity of Coumarin Derivatives by Human CYP1 Enzymes: In Vitro Enzyme Kinetics and In Silico Modeling

The Binding Specificity Determines the Cytochrome P450 3A4-Mediated Enantioselective Metabolism of Metconazole.

Human CYP2C8: Structure, Substrate Specificity, Inhibitor Selectivity, Inducers and Polymorphisms

Molecular docking and in vitro evaluations reveal the role of human cytochrome P450 3A4 in the cross-coupling metabolism of phenolic xenobiotics